Oncology Drugs - Sweden

Sweden

The Oncology Drugs market in Sweden is forecasted to achieve a revenue of SEK US$0.84bn in 2024.
This signifies an estimated annual growth rate (CAGR 2024-2029) of 6.85%, leading to a market volume of SEK US$1.17bn by 2029.
When compared globally, United States is expected to generate the highest revenue, reaching an impressive amount of US$103,900.00m in 2024.
Sweden has a strong focus on developing innovative oncology drugs, with a particular emphasis on precision medicine and targeted therapies.

Key regions: France, Europe, United Kingdom, Brazil, India

Market

Region

Region comparison

Currency

Analyst Opinion

The Oncology Drugs market in Sweden has been developing in recent years due to several factors.

Customer preferences: Swedish consumers have shown a growing demand for innovative and effective oncology drugs. They are willing to pay a premium for drugs that offer better outcomes and improved quality of life. Patients are also increasingly seeking personalized treatments that are tailored to their specific needs and genetic makeup. This has led to a rise in the use of targeted therapies and immunotherapies.

Trends in the market: The Oncology Drugs market in Sweden has been experiencing a shift towards more targeted therapies and immunotherapies. These drugs offer a more precise and effective treatment approach compared to traditional chemotherapy. The market has also seen an increase in the use of biosimilars, which are cheaper versions of biologic drugs. This trend is driven by efforts to reduce healthcare costs and increase access to treatments.

Local special circumstances: Sweden has a well-established healthcare system that provides universal coverage to its citizens. The government heavily regulates the pharmaceutical industry to ensure that drugs are safe and effective. The country also has a strong focus on research and development, with several leading pharmaceutical companies based in Sweden. This has led to a high level of innovation in the Oncology Drugs market.

Underlying macroeconomic factors: The Swedish economy has been growing steadily in recent years, with a low unemployment rate and high levels of disposable income. This has led to an increase in healthcare spending and a greater willingness to invest in innovative treatments. The government has also introduced several policies aimed at promoting the use of generic drugs and reducing healthcare costs. These factors have contributed to the growth of the Oncology Drugs market in Sweden.

Methodology

Data coverage:

Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.

Modeling approach / Market size:

Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.

Forecasts:

In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.

Additional notes:

Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.